|
| References
–
Prostate-screening,
benign enlargement and cancer |
| 6.
Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard
JL et al. Longitudinal evaluation of serum
androgen levels in men with and without prostate cancer. Prostate
1995;27:25-31.
Abstract: Androgens are thought to play a role in the pathogenesis
of prostate cancer. We evaluated androgen levels in 3 age-matched
groups of men who were part of the Baltimore Longitudinal
Study of Aging: 1) 16 men with no prostatic disease by urologic
history and exam (control group); 2) 20 men with a histologic
diagnosis of benign prostatic hyperplasia (BPH) who had
undergone simple prostatectomy; and 3) 20 men with a histologic
diagnosis of prostate cancer (16 with local/regional cancer,
and 4 with metastatic cancer). Luteinizing hormone (LH),
total testosterone (T), and free T were measured on stored
AM sera by radioimmunoassay (RIA). Free T was also calculated
from the measured concentrations of total T and sex hormone
binding globulin (SHBG). The median number of repeated sex
steroid measurements ranged from 6-9 over a period from
7-25 years prior to the diagnosis of prostate disease. There
were no significant differences in age-adjusted LH, total
T, SHBG, or calculated free T levels among the groups at
0-5, 5-10, and 10- 15 years before diagnosis. These data
suggest that there are no measurable differences in serum
testosterone levels among men who are destined to develop
prostate cancer and those without the disease
|
| back
to reference list - Prostate |
| back
to reference library menu |
|
|
|
